ESMO updates guidelines for pancreatic cancer

  • European Society for Medical Oncology

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The European Society for Medical Oncology (ESMO) has released an update to its 2015 Clinical Practice Guidelines for the treatment, diagnosis, and follow-up of pancreatic cancer.

Why this matters

Key points

  • The ESPAC-4 trial (n=732) showed better relapse-free survival (HR, 0.86; P=.082) and OS (HR, 0.82; P=.032) with gemcitabine+capecitabine than with gemcitabine alone.
  • The PRODIGE 24/CCTG PA.6 trial showed better DFS (HR, 0.59; 95% CI, 0.47-0.74) and OS (HR, 0.66; 95% CI, 0.49-0.89) with modified (m)FOLFIRINOX than gemcitabine alone, with more grade 3-4 toxicity.
  • After pancreatic resection in selected, fit patients, mFOLFIRINOX should be the first choice for adjuvant therapy. This recommendation is based on survival outcomes and the therapy’s toxicity profile.
  • Gemcitabine/capecitabine is an alternative for patients who are frail: that is, patients aged >70 years or who have an Eastern Cooperative Oncology Group performance status of 2. It is also available for patients who have any contraindications to drugs used in FOLFIRINOX.
  • Gemcitabine alone should be used only in frail patients.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit